Korea's LG In Deal With Merck KGaA
LG Household & Health Care of Korea has signed an agreement with MerckKGaA to market its off-patent biopharmaceuticals globally through the German company's worldwide sales network, reports Korea Economic Weekly.
Under the agreement, Merck will market the company's products in the USA and Europe, while LG will retain marketing rights in Asia. The deal also provides for joint marketing of additional LG products under development.
The biopharmaceuticals involved in the deal include erythropoietin, alpha and gamma interferon, G-CSF and GM-CSF, and LG hopes that the marketing agreement with Merck will help it reach its goal of 500 billion won ($555 milllion) in sales by 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze